Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 102 participants.

Also called NCT07134712

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 102 participants (planned count) (from the registry)
Sponsor
HONYA Medical Co Ltd (from the registry)
Registry
  • NCT NCT07134712
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Australia, Taiwan (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07134712. Randomized; single masking; primary purpose treatment. Start 2026-03-30 (anticipated); primary completion 2027-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of MiSaver (CB Cells) for Acute Myocardial Infarction, Phase II
Acronym
SEMIAMI
Condition
Acute Myocardial Infarction (AMI)
Intervention (Biological)
Cord Blood Nucleated cells
Lead sponsor
HONYA Medical Co Ltd (class: industry)

Record details

Record id
cardio:ct-nct07134712
Content hash
8f4b7ee3b8576478a19a20e59358fe3705be5b4c697c3ad5422eba92fdca2fa7